|4th January 2021||Joseph W Iii Marshall||3,656||Grant/award etc.||$0.00|
|4th January 2021||Joseph W Iii Marshall||4,128||Grant/award etc.||$0.00|
|27th August 2020||James Antal||30,000||Open or private sale||$7.10||$213,000.00|
|12th August 2020||Eric A Md Rose||661||Grant/award etc.||$0.00|
|7th August 2020||Eric A Md Rose||422||Payment by withholding||$314.98||$132,921.56|
|31st July 2020||Robin Elizabeth Abrams||14,138||Payment by withholding||$6.42||$90,765.96|
|31st July 2020||Robin Elizabeth Abrams||26,667||Exercise of derivative||$0.00|
|31st July 2020||Daniel J Luckshire||13,005||Payment by withholding||$6.42||$83,492.10|
|31st July 2020||Daniel J Luckshire||26,667||Exercise of derivative||$0.00|
|21st May 2020||Jeffrey B Kindler||15,000||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand.